Breaking Corporate Events, Analysed in Real Time

Aurobindo Pharma Secures USFDA Approval for First MDI Product in US$301M Market

Aurobindo Pharma has received final USFDA approval for Beclomethasone Dipropionate HFA Inhalation Aerosol, marking its entry into the metered-dose inhaler (MDI) segment. The product targets a US market valued at approximately US$301 million and will be manufactured in North Carolina.

Astal Laboratories Ltd to Raise ₹300 Crore for USFDA Pharma Unit Acquisitions

Astal Laboratories Ltd has approved a significant capital raise of up to ₹300 crore to fund its strategic expansion into the pharmaceutical sector. The company's board has also issued a mandate to scout for and acquire manufacturing facilities in India that hold prestigious international regulatory approvals.